Precision Optics Corporation, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2013, compared with fiscal 2012. Although the request metadata says “2012 Q4,” this filing reports fiscal 2013 annual results; it does not provide a complete standalone fourth-quarter income statement.
Business context
The company designs and manufactures optical systems and components, primarily medical devices for minimally invasive procedures, including endoscopes, Microprecision lenses and micro medical cameras. Military and industrial products account for approximately 10% of its business. It is pursuing commercialization of small-format imaging products and handheld 3D endoscopes.
Financial performance and liquidity
| Metric | FY 2013 | FY 2012 |
|---|---|---|
| Revenue | $2.520 million | $2.152 million |
| Gross profit / margin | $654,428 / 26.0% | $557,406 / 25.9% |
| Operating loss | $(1.233) million | $(1.285) million |
| Net income (loss) | $(1.788) million | $960,972 |
| Operating cash flow | $(1.293) million | $(1.586) million |
| Cash at year-end | $1.035 million | $145,923 |
| Current assets / current liabilities | $2.271 million / $592,886 | $1.204 million / $727,070 |
| Senior convertible notes | None outstanding | $51,250 |
Revenue rose 17.1%, reflecting higher micro-optics and surgical-visualization-system sales, partly offset by lower endoscope and coupler volumes. Gross margin was nearly unchanged; higher volume was partly offset by product mix and startup costs for new products. R&D expense, net of customer reimbursements, fell 5.2% to $630,294; SG&A increased 6.2% to $1.261 million.
The FY 2013 net loss includes a $629,000 noncash provision for settlement of registration-rights claims. FY 2012 net income included a $2.276 million gain on the sale of patents; excluding this major item, the headline year-over-year earnings comparison is not indicative of underlying operating performance. Cash increased principally following a September 2012 stock-and-warrant financing that raised $2.5 million gross. The company reported no off-balance-sheet arrangements and paid no dividends.
Changes, outlook and material matters
- Sales concentration increased: the largest customer represented 54% of FY 2013 revenue, versus 22% in FY 2012; the second largest represented 13%, versus 34%. The three largest customers accounted for 62% of year-end receivables.
- Management expects operating losses to continue until sales reach breakeven and profitable levels; the filing gives no quantified earnings or revenue guidance.
- Management described commercialization opportunities in Microprecision products and 3D endoscopy. Orders cited include a $660,000 custom-endoscope order, with requested delivery accelerated from 16 months to 10 months beginning July 2013; an earlier $1.032 million endoscope order; and an approximately $250,000 micro-camera order. Timing and conversion of customer discussions into sales remain uncertain.
- Cash used in operations improved year over year but remained substantial. Fourth-quarter operating cash use was $236,185, versus $343,539 in the preceding quarter.
- In February 2013, settlements with Special Situations, a director and another stockholder resolved registration-rights claims through share and warrant issuances and warrant-term changes, rather than cash damages. A separate stockholder demanded rescission or $179,316; the company said no lawsuit had been filed and disputed the claim.
- Management concluded disclosure controls and internal control over financial reporting were ineffective at June 30, 2013, citing material weaknesses involving segregation of accounting duties and inventory valuation. The independent auditor gave an unqualified opinion on the financial statements but was not engaged to audit internal controls.
- Key risks include customer concentration and collection exposure, fixed-price order profitability, dependence on key personnel and a limited number of suppliers, medical-device regulation, competition, and the limited liquidity and potential volatility of OTCQB shares. The filing reports substantial potential dilution from outstanding warrants and options.
Important facts for investors to verify
- Whether the cited customer orders were delivered, accepted and collected after year-end, and whether further orders reduce customer concentration.
- Cash burn, working-capital needs and financing requirements if operating losses continue.
- Progress in remediating the disclosed internal-control material weaknesses.
- Current status and potential financial impact of the stockholder demand and other settlement-related obligations.
- Current warrant and option totals, exercise terms and potential dilution; the filing gives different warrant totals in separate sections.